Nav: Home

Novel compound sparks new malaria treatment hope

March 04, 2020

A novel class of antimalarial compounds that can effectively kill malaria parasites has been developed by Australian and US researchers.

In preclinical testing, the compounds were effective against different species of malaria parasites, including the deadly Plasmodium falciparum, and at multiple stages of the parasite lifecycle. The compounds target a previously unexplored parasite pathway and could overcome existing issues of parasite drug resistance, an ongoing and increasingly urgent problem.

The researchers hope that drugs based on these early compounds will soon enter phase 1 clinical trials.

The research, a collaboration between the Walter and Eliza Hall Institute and global pharmaceutical company MSD, was published in Cell Host & Microbe.

Exciting new development

Professor Alan Cowman, an international malaria expert and deputy director at the Walter and Eliza Hall Institute, led the Australian research team, alongside MSD scientist and US team lead Dr David Olsen.

"This is an exciting new class of antimalarial compounds that could fill a critical and widening gap in our efforts to control and eliminate malaria," Professor Cowman said.

"In preclinical testing, the lead compound WM382 inhibited growth of the malaria parasite in the host and prevented transmission back to the mosquito. These results indicate that this class of compounds is very promising as a potent new treatment for malaria. We hope that drugs based on these compounds will soon progress to human phase I clinical trials."

WM382 not only killed malaria parasites in the blood, it also killed parasites in the liver and prevented parasites in the blood being transmitted to mosquitoes, he said.

"This novel class of compounds has the potential to not only cure people with malaria, but also prevent transfer of the parasite to the mosquito and, consequently, halt further transmission of the disease. This is an exciting prospect, as current antimalarial drugs kill the malaria parasite in the blood but do not fully prevent transmission," Professor Cowman said.

An emerging crisis

A major problem with current antimalarial drugs is that malaria parasites evolve and develop resistance to the drugs over time.

"Much like antibiotic resistance, malaria resistance is an emerging crisis," Professor Cowman said.

"Effective antimalarial drugs are not just critical for the infected individual, they are also critical for breaking the cycle of infection and an important way for us to reach our goal of eliminating malaria from highly endemic regions."

Once parasite resistance emerges, it can quickly spread through a region, or even globally. "In some areas, parasites are resistant to all three frontline malaria treatments. So novel drugs are urgently needed," he said.

In recent years, the focus of international efforts to develop new malaria drugs have centred on two criteria; they must target a novel process or pathway to avoid pre-existing resistance to current drugs; and they must be active at multiple stages of the parasite lifecycle.

Professor Cowman said WM382 successfully met both of these criteria.

"An exciting feature of WM382 is that it kills the malaria parasite in a very different way to current antimalarial drugs. In preclinical testing, malaria parasites that were resistant to the lethal effects of current antimalarial drugs were fully susceptible to WM382. It was also very difficult to induce resistance to this compound in malaria parasites in the lab. This is uncommon in drug discovery, and is a positive sign, as it suggests it will be harder for malaria parasites to acquire resistance in the field," Professor Cowman said.

Combatting malaria

More than 600,000 people - predominantly pregnant women and children under the age of five - die from malaria every year. According to the World Health Organization, one child in Africa continues to die from malaria every two minutes.

The malaria parasite has a complex lifecycle. Humans are infected by the bite of an infected mosquito. The parasites migrate to the liver to grow and divide undetected. It is then released into the blood, where it can be transmitted back to a mosquito and passed on to their next victim.

Professor Cowman said WM382 targeted two crucial enzymes in the malaria parasite, blocking their function and killing the parasite. "This compound has a two-pronged approach to disable the parasite, which helps explain its potency and effectiveness," Professor Cowman said. "It targets plasmepsin IX (PMIX) and plasmepsin X (PMX), two 'master regulators' that are critical for parasite survival. PMIX and PMX are involved in multiple stages of the parasite lifecycle and, because the compound hits both these targets, it is harder for parasites to develop resistance."
-end-
The research was a multidisciplinary, international collaboration between researchers with expertise in malaria biology, medicinal chemistry and drug development. Research at the Walter and Eliza Hall Institute was led by Professor Cowman, with Dr Paola Favuzza, Associate Professor Justin Boddey, Dr Brad Sleebs and colleagues. The MSD team was headed by Dr Olsen, with Dr Manuel de la Ruiz and colleagues. The research was funded by the Wellcome Trust (UK), Australian National Health and Medical Research Council and the Victorian Government.

Walter and Eliza Hall Institute

Related Malaria Articles:

Breakthrough in malaria research
An international scientific consortium led by the cell biologists Volker Heussler from the University of Bern and Oliver Billker from the Umeå University in Sweden has for the first time systematically investigated the genome of the malaria parasite Plasmodium throughout its life cycle in a large-scale experiment.
Scientists close in on malaria vaccine
Scientists have taken another big step forward towards developing a vaccine that's effective against the most severe forms of malaria.
New tool in fight against malaria
Modifying a class of molecules originally developed to treat the skin disease psoriasis could lead to a new malaria drug that is effective against malaria parasites resistant to currently available drugs.
Malaria expert warns of need for malaria drug to treat severe cases in US
The US each year sees more than 1,500 cases of malaria, and currently there is limited access to an intravenously administered (IV) drug needed for the more serious cases.
Monkey malaria breakthrough offers cure for relapsing malaria
A breakthrough in monkey malaria research by two University of Otago scientists could help scientists diagnose and treat a relapsing form of human malaria.
Getting to zero malaria cases in zanzibar
New research led by the Johns Hopkins Center for Communication Programs, Ifakara Health Institute and the Zanzibar Malaria Elimination Program suggests that a better understanding of human behavior at night -- when malaria mosquitoes are biting -- could be key to preventing lingering cases.
Widely used malaria treatment to prevent malaria in pregnant women
A global team of researchers, led by a research team at the Liverpool School of Tropical Medicine (LSTM), are calling for a review of drug-based strategies used to prevent malaria infections in pregnant women, in areas where there is widespread resistance to existing antimalarial medicines.
Protection against Malaria: A matter of balance
A balanced production of pro and anti-inflammatory cytokines at two years of age protects against clinical malaria in early childhood, according to a study led by ISGlobal, an institution supported by ''la Caixa'' Foundation.
The math of malaria
A new mathematical model for malaria shows how competition between parasite strains within a human host reduces the odds of drug resistance developing in a high-transmission setting.
Free malaria tests coupled with diagnosis-dependent vouchers for over-the-counter malaria treatment
Coupling free diagnostic tests for malaria with discounts on artemisinin combination therapy (ACT) when malaria is diagnosed can improve the rational use of ACTs and boost testing rates, according to a cluster-randomized trial published this week in PLOS Medicine by Wendy Prudhomme O'Meara of Duke University, USA, and colleagues.
More Malaria News and Malaria Current Events

Trending Science News

Current Coronavirus (COVID-19) News

Top Science Podcasts

We have hand picked the top science podcasts of 2020.
Now Playing: TED Radio Hour

Making Amends
What makes a true apology? What does it mean to make amends for past mistakes? This hour, TED speakers explore how repairing the wrongs of the past is the first step toward healing for the future. Guests include historian and preservationist Brent Leggs, law professor Martha Minow, librarian Dawn Wacek, and playwright V (formerly Eve Ensler).
Now Playing: Science for the People

#566 Is Your Gut Leaking?
This week we're busting the human gut wide open with Dr. Alessio Fasano from the Center for Celiac Research and Treatment at Massachusetts General Hospital. Join host Anika Hazra for our discussion separating fact from fiction on the controversial topic of leaky gut syndrome. We cover everything from what causes a leaky gut to interpreting the results of a gut microbiome test! Related links: Center for Celiac Research and Treatment website and their YouTube channel
Now Playing: Radiolab

The Flag and the Fury
How do you actually make change in the world? For 126 years, Mississippi has had the Confederate battle flag on their state flag, and they were the last state in the nation where that emblem remained "officially" flying.  A few days ago, that flag came down. A few days before that, it coming down would have seemed impossible. We dive into the story behind this de-flagging: a journey involving a clash of histories, designs, families, and even cheerleading. This show is a collaboration with OSM Audio. Kiese Laymon's memoir Heavy is here. And the Hospitality Flag webpage is here.